Compound ID | 161
IMT504
Class: Nucleoside analogue
| Agent Type: | Synthetic; Small molecule; Indirect acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Immunomodulator; likely stimulates innate immune system and protects against microbial invasion |
| Target Pathogen: | Active against Pseudomonas aeruginosa bacteraemia and sepsis |
| Combined with other compounds: | Yes |
| Description: | Synthetic compound; a non-CpG (a non-unmethylated cytosine-guanine) dinucleotide 24-mer oligodeoxynucleotide |
| Institute where first reported: | Mid-Atlantic BioTherapeutics, USA |
| Year first mentioned: | 2005 |
| Highest developmental phase: | Preclinical |
| Development status: | Experimental |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.